Leerink Swann Starts CellaVision AB (CLVS) at Outperform; A Rare Find In Oncology
Tweet
Share
E-mailGet Alerts CLVS Hot Sheet
Price: $0.08 --0%
Rating Summary:
7 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
7 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Leerink Swann initiates coverage on CellaVision AB (NASDAQ: CLVS) with a Outperform. Low $20's/share valuation.
Leerink analyst says, "We are initiating coverage on CLVS, a development-stage biotechnology company with three attractive oncology assets that have been assembled through in-licensing by the same team that assembled Pharmion (sold to Celgene (Nasdaq: CELG) for $2.9B in 2007). Lead program CO-101 is a lipid-conjugated gemcitabine in-licensed from Clavis Oncology in a pivotal Phase IIb study for pancreatic cancer with results expected in 2H12. CO-338 is a PARP inhibitor in-licensed from PFE (MP), which is in Phase I/II studies, while CO-1686 is an EGFR-inhibitor in-licensed from Avila and which has activity against the T790M mutation that confers resistance to Tarceva/Iressa and will be entering clinical development soon. Success with any of these programs could drive substantial upside to current valuation."
For an analyst ratings summary and ratings history on CellaVision AB click here. For more ratings news on CellaVision AB click here.
Shares of CellaVision AB closed at $13.98 yesterday.
Leerink analyst says, "We are initiating coverage on CLVS, a development-stage biotechnology company with three attractive oncology assets that have been assembled through in-licensing by the same team that assembled Pharmion (sold to Celgene (Nasdaq: CELG) for $2.9B in 2007). Lead program CO-101 is a lipid-conjugated gemcitabine in-licensed from Clavis Oncology in a pivotal Phase IIb study for pancreatic cancer with results expected in 2H12. CO-338 is a PARP inhibitor in-licensed from PFE (MP), which is in Phase I/II studies, while CO-1686 is an EGFR-inhibitor in-licensed from Avila and which has activity against the T790M mutation that confers resistance to Tarceva/Iressa and will be entering clinical development soon. Success with any of these programs could drive substantial upside to current valuation."
For an analyst ratings summary and ratings history on CellaVision AB click here. For more ratings news on CellaVision AB click here.
Shares of CellaVision AB closed at $13.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- UBS Starts Mobimo Holding AG (MOBN:SW) at Neutral
- UBS Starts Intershop Holding AG (ISN:SW) at Sell
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
